healthcare

University of Hertfordshire researchers have developed an AI forecasting model for the NHS, leveraging historical data and machine learning to predict healthcare demand. This system analyzes patient trends, workforce availability, and demographics to improve resource allocation, staffing, and patient care strategies. Focusing on system-wide operations, the model aims to shift healthcare management from reactive to proactive, enhancing efficiency and informing crucial strategic decisions. The project is ongoing and expanding its pilot testing to various healthcare settings.

Humana is implementing Google Cloud’s AI, including Gemini Enterprise for CX, with its new Agent Assist tool. This initiative aims to empower member advocates by providing real-time conversation summaries, anticipating needs, and swiftly retrieving information. The goal is to enhance support speed, personalization, and accuracy while maintaining a human-centered approach where AI acts as a co-pilot. This aims to reduce administrative burdens and improve member welfare.

Horizon1000, a Gates Foundation and OpenAI initiative, aims to integrate AI into primary healthcare clinics across Africa, starting in Rwanda, with a $50 million investment to reach 1,000 clinics by 2028. The project focuses on alleviating administrative burdens for healthcare workers, not on advanced diagnostics. This effort addresses declining international aid for health and rising child mortality by using AI to streamline patient intake, record-keeping, and guidance, thereby improving access to quality care in resource-constrained settings.

Nvidia CEO Jensen Huang believes AI will create more jobs than it displaces, viewing it as a transformative “platform shift” like personal computing or the internet. He outlined a five-layer AI architecture from energy to applications. Huang argued that AI’s efficiency gains will boost overall demand for goods and services, leading to increased hiring, citing radiology and nursing as examples where AI frees up professionals for more critical patient care. Despite high demand, he doesn’t see an immediate AI investment bubble, as supply is struggling to keep up.

OpenEvidence, an AI startup for physicians, has raised $250 million at a $12 billion valuation, bringing its total funding to $700 million in under a year. The platform, trained on medical literature, aims to assist doctors in clinical decision-making. It claims over 40% adoption among US physicians and generates revenue through advertising. Despite competition from giants like OpenAI and Anthropic, OpenEvidence leverages its specialized focus and user data as competitive advantages. The founder aims for long-term independent growth, viewing potential IPOs from other AI leaders as paving the way for future public offerings.

TSMC’s strong profits and planned expansion highlight AI’s impact on semiconductors, with the US investing heavily in Taiwan’s chip production. In retail, Amazon challenges Saks’ bankruptcy financing. Trump unveils a new healthcare plan focused on drug costs, diverging from ACA subsidy extensions. Goldman Sachs explores prediction markets, while NBCUniversal bets on a “Legendary February” of major sports events to boost viewership.

Major AI players like OpenAI, Google, and Anthropic have launched specialized medical AI tools, driven by competition. These platforms, like ChatGPT Health, MedGemma 1.5, and Claude for Healthcare, leverage multimodal LLMs fine-tuned on medical data to streamline administrative tasks such as prior authorization and claims processing. However, they are positioned as developer tools, not diagnostic products, and none currently have FDA clearance for clinical use. While benchmark performance shows improvements, real-world clinical validation and regulatory pathways remain significant hurdles. Current deployments focus on administrative workflows, not direct patient diagnosis or treatment decisions.

Zacks Small-Cap Research initiated coverage on Cosmos Health with a $4.50 price target. They highlight the company’s diversified, vertically integrated model, anticipating strong revenue growth driven by high-margin pharmaceuticals, nutraceuticals, telehealth, and AI R&D. The valuation is based on a five-year DCF analysis, factoring in U.S. market expansion, a $300 million financing facility, and digital asset strategy. Zacks also noted positive recent financial performance.

Amazon Pharmacy is expanding into the weight-loss drug market by offering Novo Nordisk’s oral Wegovy pill. This move increases patient access to the popular medication, previously dominated by injectables. Amazon aims to make treatment more accessible with pricing as low as $25 per month with insurance and $149 without. The integration with One Medical clinics further streamlines prescription fulfillment, highlighting Amazon’s growing presence in healthcare. This strategic expansion positions Amazon as a key player in reshaping weight management treatments.